stoxline Quote Chart Rank Option Currency Glossary
10X Capital Venture Acquisition Corp. III (VCXB)
10.86  -0.11 (-1%)    04-23 10:09
Open: 10.88
High: 10.91
Volume: 3,505
Pre. Close: 10.97
Low: 10.86
Market Cap: 143(M)
Technical analysis
2024-04-23 10:21:27 AM
Short term     
Mid term     
Targets 6-month :  12.73 1-year :  12.83
Resists First :  10.9 Second :  10.98
Pivot price 10.86
Supports First :  10.77 Second :  8.96
MAs MA(5) :  10.91 MA(20) :  10.84
MA(100) :  10.76 MA(250) :  10.63
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  70.5 D(3) :  86.8
RSI RSI(14): 53.7
52-week High :  10.98 Low :  10.27
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ VCXB ] has closed above bottom band by 49.8%. Bollinger Bands are 298.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 11.01 - 11.06 11.06 - 11.11
Low: 10.74 - 10.8 10.8 - 10.85
Close: 10.88 - 10.98 10.98 - 11.05
Company Description

10X Capital Venture Acquisition Corp. III does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to identify business opportunities in the field of consumer internet, e-commerce, software, healthcare, transportation/mobility, financial services, artificial intelligence, automation, data science, and Software-as-a-Service. The company was incorporated in 2021 and is based in New York, New York.

Headline News

Tue, 31 Oct 2023
Addimmune Prepares to Go Public, Initiate Phase Ib HIV Trial - BioBuzz

Mon, 18 Sep 2023
Why the First Clinical Cure for HIV Will Likely be Developed in Maryland - BioBuzz

Wed, 09 Aug 2023
Addimmune, a Clinical Stage Hiv-Focused Gene Therapy Company, to go Public Through Business Combination With ... - GlobeNewswire

Wed, 16 Nov 2022
10X Capital Hires Former CalPERS and Alaska Permanent Fund CIO Russell Read - GlobeNewswire

Tue, 16 Aug 2022
Bitcoin Miner PrimeBlock Cancels Listing Plans, Terminates $1.25B Merger With 10X Capital - CoinDesk

Mon, 21 Feb 2022
10X Capital (VCXB) Lands $300 Million For Third SPAC Effort - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Financial Services
Shell Companies
Shares Out 13 (M)
Shares Float 2 (M)
Held by Insiders 0 (%)
Held by Institutions 111.9 (%)
Shares Short 1 (K)
Shares Short P.Month 1 (K)
Stock Financials
EPS -0.08
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.25
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -3.1 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 1 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -135.75
PEG Ratio 0
Price to Book value -8.76
Price to Sales 0
Price to Cash Flow 276
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android